论文部分内容阅读
自1997年Asahara等[1]发现内皮祖细胞(endothelial progenitorcell,EPC)以来,人们对它的生物学特性及其生理、病理意义有了较多认识。EPC不仅参与胚胎期的血管发育,也存在于成年机体的骨髓及外周血液中,对出生后的血管发育和血管损伤修复起重要作用,这已被许多实验和临床所证实[2],EPC治疗血管性疾病的研究取得令人鼓舞成绩。近年来人们对EPC防治经皮冠状动脉介入术(PCI)后再狭窄的作用也做了不少探索,并取得不少进展。本文就EPC
Since the discovery of endothelial progenitorcells (EPCs) by Asahara et al [1] in 1997, people have more understanding of its biological characteristics and its physiological and pathological significance. EPC is not only involved in the development of embryonic blood vessels, but also in the bone marrow and peripheral blood of adult body, plays an important role in the development of blood vessels after birth and repair of vascular injury, which has been confirmed by many experiments and clinics [2], EPC treatment Vascular disease research has made encouraging achievements. In recent years, people have done a lot of exploration on the role of EPC in prevention and treatment of restenosis after percutaneous coronary intervention (PCI) and made a lot of progress. This article on EPC